• 1
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980; 124: 3840.
  • 2
    Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 168994.
  • 3
    O'Donnell MA, DeWolf DC. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995; 4: 189202.
  • 4
    Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin. Eur J Immunol 1999; 29: 6509.
  • 5
    Wang J, Wakeham J, Harkness R, Xing Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J Clin Invest 1999; 103: 10239.
  • 6
    Mendez-Samperio P, Trejo-Echeverria A, Ayala-Verdin H. Regulation of interleukin-12 production in human cells stimulated with Mycobacterium bovis BCG. Cell Immunol 1998; 189: 2530.
  • 7
    Matsumoto H, Suzuki K, Tsuyuguchi K et al. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG. cytokine regulation and effect of NK cells. Infect Immun 1997; 65: 440510.
  • 8
    Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 538.
  • 9
    Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990; 144: 5964.
  • 10
    Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 2000; 164: 212933.
  • 11
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155: 47782.
  • 12
    Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, Saito Y. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol 1999; 115: 1315.
  • 13
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 124851.
  • 14
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 2002; 167: 3647.
  • 15
    Elsasser-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W, Wetterauer U. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. J Urol 2000; 163: 2969.
  • 16
    Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131: 20616.
  • 17
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guérin treatment. can it predict the optimal number of instillations? J Urol 1999; 161: 6771.
  • 18
    O'Donnell MA, Chen X, DeWolf WC. Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules. J Urol 1996; 155: 1030A.
  • 19
    Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127: 206.
  • 20
    McAveney KM, Gomella LG, Lattime EC. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 1994; 39: 4016.
  • 21
    Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 101823.
  • 22
    Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur Urol 1992; 21 (Suppl. 2):1721.
  • 23
    Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 57380.
  • 24
    De Jager R, Guinan P, Lamm D. Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin. Urology 1991; 38: 50713.
  • 25
    Herr HW, Pinsky CM, Whitmore WF. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 2657.
  • 26
    Xu D, Chan WL, Leung BP et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998; 188: 148592.
  • 27
    Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M, Kurimoto M. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158: 154150.
  • 28
    Ahn HJ, Maruo S, Tomura M et al. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 1997; 159: 212531.
  • 29
    Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996; 173: 2305.
  • 30
    Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21: 1726.
  • 31
    Quiding-Jarbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun 2001; 69: 566170.
  • 32
    Kobayashi K, Kai M, Gidoh M, Nakata N, Endoh M, Singh RP, Kasama T, Saito H. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin Immunol Immunopathol 1998; 88: 22631.
  • 33
    Kobayashi K, Nakata N, Kai M, Kasama T, Hanyuda Y, Hatano Y. Decreased expression of cytokines that induce type 1 helper T cell/interferon-gamma responses in genetically susceptible mice infected with Mycobacterium avium. Clin Immunol Immunopathol 1997; 85: 1126.
  • 34
    Kim SH, Cho D, Kim TS. Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology 2001; 102: 23441.
  • 35
    Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect 2000; 2: 125763.
  • 36
    Garcia VE, Uyemura K, Sieling PA et al. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol 1999; 162: 611421.
  • 37
    Song CH, Lee JS, Nam HH et al. IL-18 production in human pulmonary and pleural tuberculosis. Scand J Immunol 2002; 56: 6118.
  • 38
    Vankayalapati R, Wizel B, Weis SE, Samten B, Girard WM, Barnes PF. Production of interleukin-18 in human tuberculosis. J Infect Dis 2000; 182: 2349.
  • 39
    O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62: 250814.
  • 40
    Luo Y, Szilvasi A, Chen X, DeWolf WC, O'Donnell MA. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Laboratory Immunol 1996; 3: 7618.
  • 41
    Luo Y, Chen X, Szilvasi A, O'Donnell MA. Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 2000; 37: 52736.
  • 42
    Luo Y, Chen X, Han R, O'Donnell MA. Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001; 123: 26470.
  • 43
    Chung MA, Luo Y, O'Donnell M, Rodriguez C, Heber W, Sharma S, Chang HR. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Cancer Res 2003; 63: 12807.
  • 44
    Snapper SB, Lugosi L, Jekkel A, Melton RE, Kieser T, Bloom BR, Jacobs Jr. WR. Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci USA 1988; 85: 698791.
  • 45
    Palendira U, Kamath AT, Feng CG, Martin E, Chaplin PJ, Triccas JA, Britton WJ. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun 2002; 70: 194956.
  • 46
    Yamada H, Kuroda E, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol 2002; 128: 528.
  • 47
    Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro. Jpn J Cancer Res 2000; 91: 53442.
  • 48
    Stover CK, De La Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 45660.
  • 49
    Huygen K, Abramowicz D, Vandenbussche P et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun 1992; 60: 28806.
  • 50
    Pang AS, Morales A. BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol 1982; 127: 12259.
  • 51
    O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. J Immunol 1999; 163: 424652.
  • 52
    Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999; 162: 2399405.
  • 53
    Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA 1996; 93: 9349.
  • 54
    Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 1996; 64: 19.
  • 55
    Mutis T, Cornelisse YE, Ottenhoff TH. Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur J Immunol 1993; 23: 218995.
  • 56
    Kinjo Y, Kawakami K, Uezu K et al. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. J Immunol 2002; 169: 3239.
  • 57
    Sugawara I, Yamada H, Kaneko H, Mizuno S, Takeda K, Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67: 25859.
  • 58
    Takeda K, Tsutsui H, Yoshimoto T et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998; 8: 38390.
  • 59
    Young S, O'Donnell M, Lockhart E, Buddle B, Slobbe L, Luo Y, De Lisle G, Buchan G. Manipulation of immune response to Mycobacterium bovis by vaccination with IL-2 and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol 2002; 80: 20915.
  • 60
    Xu D, Trajkovic V, Hunter D, Leung BP, Schulz K, Gracie JA, Mclnnes LB, Liew FY. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000; 30: 314756.
  • 61
    Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 2002; 70: 654957.